Overview

The Gene Technology Act 2000 was enacted to establish a framework for the regulation of gene technology in Australia, with a focus on protecting human health and the environment. The Act was introduced to address the need for stringent oversight of activities involving genetically modified organisms, including clinical trials of GM products. The Gene Technology Regulator, under the auspices of the Australian Parliament, is responsible for assessing and regulating such activities. The policy objective of the Act is to ensure that gene technology activities are conducted safely and ethically, minimising any potential risks to human health and the environment. The Regulator is currently reviewing a clinical trial application for a genetically modified influenza vaccine by Clinical Network Services (CNS) Pty Ltd, inviting public submissions on the associated Risk Assessment and Risk Management Plan to inform its decision-making process.

Scope and Application

The Gene Technology Act 2000 (Cth), as amended by the Gene Technology Amendment (Clinical Trials) Regulations 2019, applies to this clinical trial proposal for a genetically modified influenza vaccine by Clinical Network Services (CNS) Pty Ltd. This Act governs the regulation of activities involving genetically modified organisms (GMOs) and their products in Australia, ensuring the protection of human health and the environment. The application to conduct the clinical trial falls under the purview of the Gene Technology Regulator, who is responsible for assessing and approving such activities. The clinical trial, which will be conducted at up to four clinical facilities in major Australian cities and involve up to 240 participants over three years, must comply with the provisions of this Act, including the submission of a Risk Assessment and Risk Management Plan (RARMP) to evaluate and mitigate potential risks. The consultation on the RARMP and related information is open to the public to gather written submissions by 13 May 2020, providing an opportunity for stakeholders to comment on the human health and environmental safety aspects of the proposed trial. The Regulator's decision to issue a licence will be based on this feedback and the comprehensive assessment of the RARMP.

Key Provisions

The legislation, specifically section 52A, outlines the primary provisions of the Gene Technology Act 2000 (Cth), which allows the Gene Technology Regulator to assess an application for a clinical trial of a genetically modified (GM) influenza vaccine. This application, made by Clinical Network Services (CNS) Pty Ltd, aims to conduct the trial under controlled conditions at up to four clinical facilities in major Australian cities. Section 52A mandates the Regulator to prepare a Risk Assessment and Risk Management Plan (RARMP) for this purpose, which serves as a critical document for evaluating the potential risks to human health, safety, and the environment associated with the trial. The Regulator is required to consider the RARMP and any relevant submissions when deciding whether to issue a licence for the trial. Under section 52A, Clinical Network Services (CNS) Pty Ltd, as the applicant, has specific obligations. They must provide comprehensive information about the proposed trial, including details about the clinical facilities, the number of participants, and the duration of the trial. Additionally, the applicant must ensure that all necessary safety measures and risk management strategies are included in the RARMP. The obligation extends to promptly responding to any queries or additional information requests from the Regulator to facilitate a thorough assessment. Section 52A also places a responsibility on the Regulator to consider any written submissions received by the specified deadline, which is 13 May 2020, to ensure that the decision-making process is transparent and inclusive. Failure to comply with the requirements set out in the Gene Technology Act 2000 (Cth) can lead to serious consequences. Section 52A specifies that any breach of the Act or non-compliance with the terms of a licence may result in enforcement actions. The Regulator has the authority to take civil or criminal action against entities or individuals found in breach of the Act. Civil penalties can include fines of up to $66,000 for individuals and $330,000 for corporations, while criminal penalties can result in fines of up to $660,000 for individuals and $3.3 million for corporations, depending on the severity and nature of the breach. These stringent penalties underscore the importance of adhering to the provisions of the Act to protect public health and safety.